Meta description: This report covers NowFuture OTC test usability and clinical validation for SARS CoV 2 and influenza in anterior nasal samples and regulatory implications.
As of February 11, 2026, Biocrucible Ltd advances its pursuit of regulatory clearance for the NowFuture digital test deployed in an OTC setting. The study focuses on usability and clinical performance for detecting SARS CoV 2, influenza A and influenza B in anterior nasal samples. The registry entry is listed on ClinicalTrials.gov with the identifier NCT07399249 and shows Biocrucible Ltd as sponsor. The status is not yet recruiting.
What changed for NowFuture OTC testing?
The entry titled Usability and Clinical Validation of the NowFuture Digital Flu and COVID Test in Anterior Nasal Samples for Over the Counter Use outlines a triage oriented diagnostic approach. The device aims to detect SARS CoV 2, influenza A and influenza B in a single manual workflow using anterior nasal samples. The source text notes the study is not yet recruiting and lists Biocrucible Ltd as sponsor. These elements signal a push to align home testing with regulatory expectations for performance and user experience in an OTC setting.
Study scope and design
Registry details show the trial covers three respiratory viruses. The intervention is a diagnostic test for SARS CoV 2, influenza A and influenza B. The target population includes individuals with suspected infection or exposure. The ClinicalTrials.gov listing provides the registry identifier NCT07399249 and a direct link to the page with terms. The status Not yet recruiting indicates prospective data collection once enrollment begins. Preparedness for regulatory submission will hinge on usability results and analytical performance data gathered in anterior nasal sampling. For readers seeking background context, two related regulatory posts are noted and internal links to those discussions are provided for context: Regulatory Affairs OTC Diagnostics and Technology Digital Diagnostics.
External reference is available via the ClinicalTrials.gov page at ClinicalTrials.gov record NCT07399249 which serves as the primary registry for this study. This article also offers a compact view of the sponsor and the not yet recruiting status to inform readers about timing and data expectations.
Intended use and device highlights
The description highlights a digital readout and an anterior nasal sampling approach. While exact performance metrics are not provided in the source text, the trial design signals a focus on ease of use, clear instructions for lay users and data capture suitable for regulatory evaluation. The sponsor statement is factual and remains within the scope of the registry information.
Sponsor and funding
Biocrucible Ltd is listed as the sponsor of the trial. The source text does not reveal additional funding sources. The not yet recruiting status implies the company intends to collect usability and clinical data before a formal submission for regulatory clearance. The alignment with MDR style requires explicit intended use, claimed performance claims only as statements of purpose, and clear safety considerations for device users.
Potential impact for patients and clinicians
If the study advances and reports favorable usability data, clinicians may see an OTC diagnostic option that supports rapid triage for respiratory infections. For patients, the option promises convenient access to a multi pathogen test using a simple anterior nasal sample. Regulators will examine whether data on user performance and diagnostic accuracy support a safe and effective OTC device pathway. The absence of published results means readers should monitor the registry and sponsor updates for concrete evidence.
Regulatory implications
Under MDR principles the device would be evaluated for intended use, performance characteristics and safety signs. Data from usability studies and clinical accuracy contribute to the evidence package needed for clearance. Statements attributed to the sponsor in the registry should be treated as company statements and not as regulatory findings. The clinical validation plan must address potential user misuses and failure modes in an OTC environment. This article summarizes the current state and directs readers to the registry for the official record.
Next steps
The path forward includes enrolling participants, collecting performance data for the three pathogen targets and compiling the results for regulatory assessment. Stakeholders should follow the ClinicalTrials.gov listing for status updates and any new publications arising from this work. The sponsor may also provide additional details through official communications or future postings.
FAQ
- What is the NowFuture test aimed to detect and how is it used? The test targets SARS CoV 2 and influenza A and B using anterior nasal samples and is intended for OTC use.
- Who sponsors the study? Biocrucible Ltd is listed as the sponsor in the registry.
- Where can the registry be found? The study is registered on ClinicalTrials.gov with the identifier NCT07399249.
- What type of samples are used? Anterior nasal samples are used in this study.
- Is the study recruiting now? The record shows Not yet recruiting at this time.
Conclusion
The NowFuture study illustrates ongoing regulatory oriented efforts to validate a tri pathogen diagnostic for OTC use. The outcome will depend on usability and clinical performance data in anterior nasal sampling. Stakeholders should monitor the official registry and sponsor communications for definitive results.
Disclaimer
This article is for professional readers and is not legal advice. It summarizes a registry entry and does not establish regulatory conclusions.
Announcement line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07399249?term=medical+device